Developer docs
API playgroundTry for free, no card

Search company profiles

Actio Biosciences

Full company profile

uuid0000a3s

Namestring
Actio Biosciences
Legal namestring
Actio Biosciences, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Actio Biosciences is a clinical-stage biotechnology company founded in October 2021 in San Diego, California, developing precision small molecule therapeutics for rare and genetically defined diseases. The company is built around its proprietary Rare Disease Target Atlas, a human genetics platform that combines Mendelian genetics, bioinformatics, and medicinal chemistry to identify and validate drug targets derived from rare-disease biology, then expand those insights into more prevalent indications under what Actio calls its "One to Many" strategy. Its pipeline comprises three programs: ABS-1230, an oral KCNT1 inhibitor currently in the KYRON Phase 1b/2 trial for KCNT1-related epilepsy; ABS-0871, an oral TRPV4 inhibitor that completed Phase 1a in healthy volunteers for Charcot-Marie-Tooth disease type 2C (CMT2C); and a third undisclosed-target discovery program in genetic epilepsy with planned CNS expansion.

The company's discovery engine integrates target identification from rare Mendelian genes, mutation-agnostic small molecule design, transgenic-mouse model characterization under a partnership with The Jackson Laboratory Rare Disease Translational Center, and population-genetics/ML-driven indication expansion. Both lead programs have received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, with ABS-1230 also accepted into the FDA's Rare Disease Evidence Principles (RDEP) process. The initial target populations are small—an estimated ~2,500 U.S. patients each for KCNT1-related epilepsy and TRPV4-positive CMT2C—and there are currently no approved disease-modifying therapies for either indication.

Actio is pre-revenue, funded by $121 million in cumulative equity financing: a $55 million Series A in September 2023 led by Canaan and DROIA Ventures, and a $66 million Series B in June 2025 co-led by Regeneron Ventures and Deerfield Management. Future revenue is expected to derive from direct commercialization of pipeline assets in the United States (and via the Australia-based Phase 1a), out-licensing, or partnership transactions with larger pharmaceutical companies; the company currently has no commercial products or pricing model.

Short descriptiontext

Actio Biosciences is a clinical-stage biotechnology company using a proprietary genetics platform to develop oral small molecule precision medicines for rare Mendelian diseases, with two clinical-stage programs targeting KCNT1-related epilepsy and Charcot-Marie-Tooth disease type 2C.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, precision medicine drugs, small molecule discovery, Mendelian genetics platform, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue clinical-stage pipeline
TypeLicensing Royalties
Description

Actio Biosciences is a clinical-stage biotechnology company with no approved or commercialized products. Current revenue model is not yet established; future revenue is expected to derive from commercialization of pipeline assets (ABS-1230, ABS-0871, third program) through direct sales, licensing, or partnerships with larger pharmaceutical companies.

actiobiosciences.com
2Capital funding (Series A and B)
TypeManaged Services
Description

Operations are funded through equity financing rounds — $55M Series A (Sept 2023) led by Canaan and DROIA Ventures, and $66M Series B (June 2025) co-led by Regeneron Ventures and Deerfield Management, with no current product-based revenue.

actiobiosciences.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1KYRON
Description

Name of Actio's Phase 1b/2 clinical trial evaluating ABS-1230 in children and young adults aged one month through 21 years with KCNT1-related epilepsy; also represented by the Kyron trial logo at ActioTrials.com.

actiobiosciences.com
Core offering1 text field

Actio Biosciences is a clinical-stage biotechnology company that uses a proprietary human genetics platform called the Rare Disease Target Atlas—combining Mendelian genetics, bioinformatics, and medicinal chemistry—to discover and develop precision small molecule drugs. Its pipeline includes ABS-1230 (a KCNT1 inhibitor for KCNT1-related epilepsy), ABS-0871 (a TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C), and an undisclosed third genetic-epilepsy program, with plans to expand each rare-disease program into more prevalent indications sharing the same underlying biology.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Actio Biosciences is a clinical-stage biotechnology company built around a single genetics-driven precision medicine platform — the proprietary Rare Disease Target Atlas — which combines a vast rare-disease target database with advanced bioinformatics, Mendelian genetics, biology, and medicinal chemistry. On top of this shared platform sit three pipeline modules: ABS-1230 (a KCNT1 inhibitor currently in the KYRON Phase 1b/2 trial for KCNT1-related epilepsy), ABS-0871 (a TRPV4 inhibitor that completed Phase 1a for Charcot-Marie-Tooth disease type 2C), and a third undisclosed-target program in Discovery for genetic epilepsy with CNS expansion. Each clinical-stage module is designed to be developed first in a rare Mendelian indication and then expanded into more prevalent diseases sharing the same underlying biology, an approach Actio calls "from one to many."

Product and service3 records
1ABS-1230
CategoryClinical-stage oral small molecule drug candidate
Description

Potent and selective orally available small molecule inhibitor of the KCNT1 potassium ion channel, designed to treat KCNT1-related epilepsy (a rare pediatric developmental epileptic encephalopathy) and being explored for additional genetic epilepsies. Holds FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, and was accepted into the FDA Rare Disease Evidence Principles process.

2ABS-0871
CategoryClinical-stage oral small molecule drug candidate
Description

First-in-class orally available small molecule inhibitor of the TRPV4 calcium-permeable ion channel being developed initially for Charcot-Marie-Tooth disease type 2C (CMT2C) and TRPV4-related neuromuscular and bone disorders, with potential expansion into overactive bladder. Holds FDA Rare Pediatric Disease, Fast Track, and Orphan Drug designations for CMT2C.

3Program 3 (Undisclosed Target)
CategoryDiscovery-stage oral small molecule drug candidate
Description

Third pipeline program at the end of the Discovery phase targeting an undisclosed gene for a rare genetic epilepsy, with planned expansion into other central nervous system (CNS) disorders. Actio owns full rights to the program.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Actio established a partnership with the Rare Disease Translational Center at The Jackson Laboratory to develop and implement new transgenic mouse models of rare disease pathways. The partnership enables evaluation of targets and phenotypes of interest in high-quality genetically engineered mouse models at scale, supporting Actio's lead TRPV4 program and broader pipeline.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Actio is a STAR Alliance Partner of the Charcot-Marie-Tooth Association. The collaboration supported ABS-0871's receipt of FDA Orphan Drug and Rare Pediatric Disease Designations in August 2024 via the CMT Association's Patients as Partners platform, and continues to support patient outreach for ABS-0871's clinical development in CMT2C.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Advocacy partnership with the KCNT1 Epilepsy Foundation to support patient education, family resources and recruitment for ABS-1230 clinical trials. The Foundation's co-founder Justin West, M.D., has publicly endorsed Actio's KYRON Phase 1b/2 trial.

4Ben Cravatt, Ph.D. (Scripps Research Institute)
Strategic tierCoreTypeOthers
Description

Professor and Norton B. Gilula Chair of Chemical Biology at The Scripps Research Institute; joined Actio's Board of Directors in May 2024. Brings chemical proteomics expertise aligned with Actio's biology-chemistry-genetics integration.

actiobiosciences.com
5Emil Kakkis, M.D., Ph.D. (Ultragenyx)
Strategic tierCoreTypeOthers
Description

CEO, president and director of Ultragenyx; joined Actio's Board of Directors in July 2024. Brings rare disease drug development expertise and longstanding advocacy through the EveryLife Foundation for Rare Diseases.

actiobiosciences.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage genetics-driven biotech that translates insights from rare genetic variants into small molecule therapies for both rare and common diseases - directly comparable to Actio's 'One to Many' Mendelian-genetics platform approach.

TypeDirect peer
Description

Genetic-disease focused biotech building multiple precision medicine programs from genetically validated targets, including in rare epilepsies and rare neuromuscular disease - directly comparable to Actio's genetically validated small molecule pipeline.

TypeDirect peer
Description

Clinical-stage company developing therapies for genetic epilepsies and other CNS disorders driven by defined genetic mutations - directly comparable to Actio's KCNT1 program and broader genetic epilepsy pipeline.

TypeDirect peer
Description

Clinical-stage company developing treatments for epilepsy and other neurological disorders, including genetically defined epilepsies - directly comparable to Actio's KCNT1-related epilepsy program and ABS-1230.

TypeBroad incumbent
Description

Established commercial-stage rare disease company led by Emil Kakkis (on Actio's board) with multiple approved and clinical-stage therapies for rare genetic diseases - provides a mature comparable for Actio's rare disease development model and commercial pathway.

TypeBroad incumbent
Description

Large commercial rare-disease biotech with multiple approved therapies for ultra-rare genetic conditions, including rare neuromuscular disorders - directly comparable to Actio's CMT2C (TRPV4) program in target patient profile and regulatory approach.

TypeEmerging player
Description

Emerging clinical-stage company using regulatory genomics to develop RNA-based therapeutics for rare genetic diseases - comparable to Actio in platform-driven rare disease strategy and stage.

TypeEmerging player
Description

Clinical-stage company developing antisense oligonucleotide medicines for genetic epilepsies and other rare genetic diseases - closely comparable in patient population and disease area to Actio's genetic epilepsy pipeline.

TypeOthers
Description

Large biopharmaceutical company whose Regeneron Ventures arm co-led Actio's Series B; Regeneron is a leading developer of genetics-based therapeutics and a natural strategic acquirer or partner for Actio's pipeline.

TypeEmerging player
Description

Established antisense RNA therapeutics company with multiple rare disease programs including in rare neuromuscular disorders and genetic neurological diseases - adjacent comparable in modality and indication overlap with Actio's TRPV4 and KCNT1 programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Actio Biosciences

Rare Disease Therapeuticsactiobiosciences.com

Actio Biosciences is a clinical-stage biotechnology company using a proprietary genetics platform to develop oral small molecule precision medicines for rare Mendelian diseases, with two clinical-stage programs targeting KCNT1-related epilepsy and Charcot-Marie-Tooth disease type 2C.

What Actio Biosciences does

Actio Biosciences is a clinical-stage biotechnology company founded in October 2021 in San Diego, California, developing precision small molecule therapeutics for rare and genetically defined diseases. The company is built around its proprietary Rare Disease Target Atlas, a human genetics platform that combines Mendelian genetics, bioinformatics, and medicinal chemistry to identify and validate drug targets derived from rare-disease biology, then expand those insights into more prevalent indications under what Actio calls its "One to Many" strategy. Its pipeline comprises three programs: ABS-1230, an oral KCNT1 inhibitor currently in the KYRON Phase 1b/2 trial for KCNT1-related epilepsy; ABS-0871, an oral TRPV4 inhibitor that completed Phase 1a in healthy volunteers for Charcot-Marie-Tooth disease type 2C (CMT2C); and a third undisclosed-target discovery program in genetic epilepsy with planned CNS expansion.

The company's discovery engine integrates target identification from rare Mendelian genes, mutation-agnostic small molecule design, transgenic-mouse model characterization under a partnership with The Jackson Laboratory Rare Disease Translational Center, and population-genetics/ML-driven indication expansion. Both lead programs have received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, with ABS-1230 also accepted into the FDA's Rare Disease Evidence Principles (RDEP) process. The initial target populations are small—an estimated ~2,500 U.S. patients each for KCNT1-related epilepsy and TRPV4-positive CMT2C—and there are currently no approved disease-modifying therapies for either indication.

Actio is pre-revenue, funded by $121 million in cumulative equity financing: a $55 million Series A in September 2023 led by Canaan and DROIA Ventures, and a $66 million Series B in June 2025 co-led by Regeneron Ventures and Deerfield Management. Future revenue is expected to derive from direct commercialization of pipeline assets in the United States (and via the Australia-based Phase 1a), out-licensing, or partnership transactions with larger pharmaceutical companies; the company currently has no commercial products or pricing model.

Actio Biosciences firmographics

Firmographics
Name
Actio Biosciences
Legal name
Actio Biosciences, Inc.
Website
https://actiobiosciences.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Actio Biosciences is a clinical-stage biotechnology company using a proprietary genetics platform to develop oral small molecule precision medicines for rare Mendelian diseases, with two clinical-stage programs targeting KCNT1-related epilepsy and Charcot-Marie-Tooth disease type 2C.
Ownership category
akta.pro rank

Actio Biosciences industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Precision medicine drugs
  • Small molecule discovery
  • Mendelian genetics platform
  • Clinical-stage biotechnology

Where Actio Biosciences is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Actio Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pre-revenue clinical-stage pipeline: Actio Biosciences is a clinical-stage biotechnology company with no approved or commercialized products. Current revenue model is not yet established; future revenue is expected to derive from commercialization of pipeline assets (ABS-1230, ABS-0871, third program) through direct sales, licensing, or partnerships with larger pharmaceutical companies.
  2. Capital funding (Series A and B): Operations are funded through equity financing rounds — $55M Series A (Sept 2023) led by Canaan and DROIA Ventures, and $66M Series B (June 2025) co-led by Regeneron Ventures and Deerfield Management, with no current product-based revenue.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Actio Biosciences product offering

Product offering

Core offering

Actio Biosciences is a clinical-stage biotechnology company that uses a proprietary human genetics platform called the Rare Disease Target Atlas—combining Mendelian genetics, bioinformatics, and medicinal chemistry—to discover and develop precision small molecule drugs. Its pipeline includes ABS-1230 (a KCNT1 inhibitor for KCNT1-related epilepsy), ABS-0871 (a TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C), and an undisclosed third genetic-epilepsy program, with plans to expand each rare-disease program into more prevalent indications sharing the same underlying biology.

Product overview

Actio Biosciences is a clinical-stage biotechnology company built around a single genetics-driven precision medicine platform — the proprietary Rare Disease Target Atlas — which combines a vast rare-disease target database with advanced bioinformatics, Mendelian genetics, biology, and medicinal chemistry. On top of this shared platform sit three pipeline modules: ABS-1230 (a KCNT1 inhibitor currently in the KYRON Phase 1b/2 trial for KCNT1-related epilepsy), ABS-0871 (a TRPV4 inhibitor that completed Phase 1a for Charcot-Marie-Tooth disease type 2C), and a third undisclosed-target program in Discovery for genetic epilepsy with CNS expansion. Each clinical-stage module is designed to be developed first in a rare Mendelian indication and then expanded into more prevalent diseases sharing the same underlying biology, an approach Actio calls "from one to many."

Differentiator

Problem solved

Functional benefit

Brands

  • KYRON: Name of Actio's Phase 1b/2 clinical trial evaluating ABS-1230 in children and young adults aged one month through 21 years with KCNT1-related epilepsy; also represented by the Kyron trial logo at ActioTrials.com.

Products and services

  • ABS-1230 Potent and selective orally available small molecule inhibitor of the KCNT1 potassium ion channel, designed to treat KCNT1-related epilepsy (a rare pediatric developmental epileptic encephalopathy) and being explored for additional genetic epilepsies. Holds FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, and was accepted into the FDA Rare Disease Evidence Principles process.
  • ABS-0871 First-in-class orally available small molecule inhibitor of the TRPV4 calcium-permeable ion channel being developed initially for Charcot-Marie-Tooth disease type 2C (CMT2C) and TRPV4-related neuromuscular and bone disorders, with potential expansion into overactive bladder. Holds FDA Rare Pediatric Disease, Fast Track, and Orphan Drug designations for CMT2C.
  • Program 3 (Undisclosed Target) Third pipeline program at the end of the Discovery phase targeting an undisclosed gene for a rare genetic epilepsy, with planned expansion into other central nervous system (CNS) disorders. Actio owns full rights to the program.

Companies that use Actio Biosciences

Customer profile

Segments3 records

Ideal customer profiles2 records

Actio Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Actio Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • The Jackson Laboratory (JAX)flagshipStrategic or Co-development PartnerActio established a partnership with the Rare Disease Translational Center at The Jackson Laboratory to develop and implement new transgenic mouse models of rare disease pathways. The partnership enables evaluation of targets and phenotypes of interest in high-quality genetically engineered mouse models at scale, supporting Actio's lead TRPV4 program and broader pipeline.
  • Charcot-Marie-Tooth AssociationcoreStrategic or Co-development PartnerActio is a STAR Alliance Partner of the Charcot-Marie-Tooth Association. The collaboration supported ABS-0871's receipt of FDA Orphan Drug and Rare Pediatric Disease Designations in August 2024 via the CMT Association's Patients as Partners platform, and continues to support patient outreach for ABS-0871's clinical development in CMT2C.
  • KCNT1 Epilepsy FoundationcoreGTM or Marketing PartnerAdvocacy partnership with the KCNT1 Epilepsy Foundation to support patient education, family resources and recruitment for ABS-1230 clinical trials. The Foundation's co-founder Justin West, M.D., has publicly endorsed Actio's KYRON Phase 1b/2 trial.
  • Ben Cravatt, Ph.D. (Scripps Research Institute)coreOthersProfessor and Norton B. Gilula Chair of Chemical Biology at The Scripps Research Institute; joined Actio's Board of Directors in May 2024. Brings chemical proteomics expertise aligned with Actio's biology-chemistry-genetics integration.
  • Emil Kakkis, M.D., Ph.D. (Ultragenyx)coreOthersCEO, president and director of Ultragenyx; joined Actio's Board of Directors in July 2024. Brings rare disease drug development expertise and longstanding advocacy through the EveryLife Foundation for Rare Diseases.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Actio Biosciences competitors and assessment

Company assessment

Direct peers

  • Maze Therapeutics: Clinical-stage genetics-driven biotech that translates insights from rare genetic variants into small molecule therapies for both rare and common diseases - directly comparable to Actio's 'One to Many' Mendelian-genetics platform approach.
  • BridgeBio Pharma: Genetic-disease focused biotech building multiple precision medicine programs from genetically validated targets, including in rare epilepsies and rare neuromuscular disease - directly comparable to Actio's genetically validated small molecule pipeline.
  • Praxis Precision Medicines: Clinical-stage company developing therapies for genetic epilepsies and other CNS disorders driven by defined genetic mutations - directly comparable to Actio's KCNT1 program and broader genetic epilepsy pipeline.
  • Xenon Pharmaceuticals: Clinical-stage company developing treatments for epilepsy and other neurological disorders, including genetically defined epilepsies - directly comparable to Actio's KCNT1-related epilepsy program and ABS-1230.

Broad incumbents

  • Ultragenyx Pharmaceutical: Established commercial-stage rare disease company led by Emil Kakkis (on Actio's board) with multiple approved and clinical-stage therapies for rare genetic diseases - provides a mature comparable for Actio's rare disease development model and commercial pathway.
  • BioMarin Pharmaceutical: Large commercial rare-disease biotech with multiple approved therapies for ultra-rare genetic conditions, including rare neuromuscular disorders - directly comparable to Actio's CMT2C (TRPV4) program in target patient profile and regulatory approach.

Emerging players

  • CAMP4 Therapeutics: Emerging clinical-stage company using regulatory genomics to develop RNA-based therapeutics for rare genetic diseases - comparable to Actio in platform-driven rare disease strategy and stage.
  • Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide medicines for genetic epilepsies and other rare genetic diseases - closely comparable in patient population and disease area to Actio's genetic epilepsy pipeline.
  • Ionis Pharmaceuticals: Established antisense RNA therapeutics company with multiple rare disease programs including in rare neuromuscular disorders and genetic neurological diseases - adjacent comparable in modality and indication overlap with Actio's TRPV4 and KCNT1 programs.

Others

  • Regeneron Pharmaceuticals: Large biopharmaceutical company whose Regeneron Ventures arm co-led Actio's Series B; Regeneron is a leading developer of genetics-based therapeutics and a natural strategic acquirer or partner for Actio's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Actio Biosciences social profiles

Digital presence

Actio Biosciences compliance and trust

Trust signal

Compliance8 records

Actio Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Actio Biosciences leadership team

Management profile

Number of profiles

Profiles10 records

Actio Biosciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Actio Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actio Biosciences

What does Actio Biosciences do?

Actio Biosciences is a clinical-stage biotechnology company that uses a proprietary human genetics platform called the Rare Disease Target Atlas—combining Mendelian genetics, bioinformatics, and medicinal chemistry—to discover and develop precision small molecule drugs. Its pipeline includes ABS-1230 (a KCNT1 inhibitor for KCNT1-related epilepsy), ABS-0871 (a TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C), and an undisclosed third genetic-epilepsy program, with plans to expand each rare-disease program into more prevalent indications sharing the same underlying biology.

Is Actio Biosciences a public or private company?

Actio Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Actio Biosciences founded?

Actio Biosciences was founded in 2021. It employs 11 to 50 people.

Where is Actio Biosciences based?

Actio Biosciences is headquartered in San Diego, United States, in the North America region.

How does Actio Biosciences make money?

Two revenue lines are on record. Pre-revenue clinical-stage pipeline is the primary driver. The others are capital funding (Series A and B).

Who are Actio Biosciences's main competitors?

Direct peers on record are Maze Therapeutics, BridgeBio Pharma, Praxis Precision Medicines and Xenon Pharmaceuticals. Broad incumbents are Ultragenyx Pharmaceutical and BioMarin Pharmaceutical. Emerging players are CAMP4 Therapeutics, Stoke Therapeutics and Ionis Pharmaceuticals. Regeneron Pharmaceuticals is listed as an others.

Does Actio Biosciences have an API?

No public API is recorded for Actio Biosciences.

What industry is Actio Biosciences in?

Actio Biosciences's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizSetara Biosciences Raises $90 Million Series A Following Jazz Pharmaceuticals’ Acquisition of ActioSetara Biosciences raised $90 million in a Series A following Jazz Pharmaceuticals' acquisition of Actio Biosciences' lead drug development program. The financing will support clinical development of STAR-0871 for CMT2C and overactive bladder, with a Phase 1b study planned in 2027. The company also plans to advance earlier-stage discovery programs.The Pharma LetterSetara launches with $90 million Series A after Jazz buys Actio’s lead programSetara Biosciences, formed after Jazz Pharmaceuticals acquired Actio, raised $90 million in a Series A to advance Actio's pipeline, led by a TRPV4 inhibitor for rare neuromuscular disease and overactive bladder. Jazz acquired Actio for its lead program ABS-1230, an investigational therapy for KCNT1-related epilepsy, in a deal worth $820 million upfront and up to $500 million in contingent consideration.BioSpaceNew biotech Setara forms with $90M to take on Jazz’s bonus rare disease programsSetara Biosciences was formed with $90 million in Series A funding to develop small molecule precision medicine programs from Jazz's acquired Actio. Its lead asset, STAR-0871, targets Charcot-Marie-Tooth disease type 2C and overactive bladder, with a Phase 1b study planned for 2027.BioPharma DiveWith Setara, the team behind Actio opens its second actSetara Biosciences, the team behind Actio, launched with $90 million in financing to develop a drug for Charcot-Marie-Tooth and overactive bladder. Its lead program STAR-0871, which blocks the TRPV4 ion channel, is set for a Phase 1b study by year-end. The company also has discovery-stage programs for epilepsy and migraines.FierceBiotechJazz's $820M Actio buyout gives rise to Setara, armed with $90M series ASetara Biosciences, a spinout from Jazz Pharmaceuticals' $820M Actio acquisition, raised $90M in Series A financing to advance its neuroscience pipeline. The company plans a phase 1b trial of STAR-0871 for CMT2C in 2027 and a phase 2a study for overactive bladder.AInvestJazz Pharmaceuticals: Price the Ziihera Launch, Not the Actio AcquisitionJazz Pharmaceuticals paid $820 million for Actio's epilepsy drug ABS-1230, but the deal is immaterial to near-term earnings. The stock's rally is driven by Ziihera's new first-line stomach cancer approval, with Q3 expected to show launch traction. Investors should wait for Ziihera's ramp before buying.PR NewswireJazz Pharmaceuticals Completes Acquisition of Actio BiosciencesJazz Pharmaceuticals completed its acquisition of Actio Biosciences for $820 million upfront, making Actio a wholly-owned subsidiary. The deal adds ABS-1230, a clinical-stage KCNT1 inhibitor for KCNT1-related epilepsy, which has received FDA Fast Track and Orphan Drug designations. Jazz plans to advance the therapy rapidly with its development capabilities.Labiotech.euTop biotech deals in August 2026August 2026 saw sustained biotech deals, led by Lilly's $2.875 billion acquisition of Merida Biosciences and Jazz's $820 million purchase of Actio Biosciences. Other deals included Tarsus's $450 million buy of Alkeus, LEO's $435 million acquisition of Tanabe's Dersimelagon, and Werewolf's merger with Ambros. Collaborations also covered ADCs and ion channel platforms.BioWorldJazz-Actio $1B+ deal one of many efforts in epilepsyJazz Pharmaceuticals agreed to acquire Actio Biosciences for $1.32 billion, including its lead epilepsy drug ABS-1230. The deal reflects growing biopharma interest in epilepsy, a disease with significant unmet need.YahooJazz Pharma buys the only shot at a disease with no FDA treatmentJazz Pharmaceuticals agreed to acquire Actio Biosciences for up to $1.32 billion to secure ABS-1230, an experimental therapy targeting KCNT1-related childhood epilepsy. The deal addresses a rare disease with no existing FDA-approved treatments in the United States and is expected to close in the fourth quarter of 2026 subject to regulatory clearance.